MedPal Enters At-Home Blood Testing Market

20 March 2026

MedPal AI plc

("MedPal AI" or the "Company")

MedPal Enters At-Home Blood Testing Market

MedPal AI (AIM: MPAL, FRA: Z1N), the UK digital health and AI company, today announces its entry into the at-home blood testing market with the launch of the MedPal weight loss blood test.

Designed for users of GLP-1 medications such as Mounjaro and Wegovy, who require regular blood tests to monitor their health, the clinically validated kit is the first in a diagnostics range planned for introduction by the Company through the course of 2026. It adds a third revenue stream alongside the Company's AI wellness app and automated pharmacy operations at MedPal.clinic.

Samples are collected at home using the virtually painless Tasso+ device and analysed by a UKAS-accredited laboratory (ISO 15189). The results are delivered directly into the MedPal app within 48 hours, combining with data from over 100 wearables powered by Google's Vertex AI to create comprehensive health profiles and personalised recommendations.

Initially the kits are to be introduced exclusively to existing MedPal app users.  A broader range of tests - covering general health, men's health, women's hormonal health and wellness panels - will roll out throughout 2026.

Jason Drummond, CEO & Founder of MedPal AI commented

"Blood testing is the missing layer in consumer health. By combining wearables, blood biomarkers, AI insights and pharmacy fulfilment in one ecosystem, we can now take users seamlessly from insight to diagnosis to treatment.".

Enquiries:

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.